SEC Form 4
FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
| 2. Issuer Name and Ticker or Trading Symbol Predictive Oncology Inc. [ POAI ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| ||||||||||||||||||||||||
3. Date of Earliest Transaction (Month/Day/Year) 09/04/2020 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 77(4) | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Options | $1,500 | 09/04/2020 | D(1) | 53 | (2) | 08/13/2022 | Common Stock | 53 | $0 | 0 | D | ||||
Stock Options (Right to buy) | $1.54 | 09/04/2020 | A(1) | 53 | (2) | 08/13/2022 | CommonStock | 53 | $0 | 53 | D | ||||
Stock Options (Right to buy) | $1,481.25 | 09/04/2020 | D(1) | 42 | (2) | 08/29/2023 | Common Stock | 42 | $0 | 0 | D | ||||
Stock Options (Right to buy) | $1.54 | 09/04/2020 | A(1) | 42 | (2) | 08/29/2023 | Common Stock | 42 | $0 | 42 | D | ||||
Stock Options (Right to buy) | $4,312.5 | 09/04/2020 | D(1) | 14 | (2) | 03/07/2024 | Common Stock | 14 | $0 | 0 | D | ||||
Stock Options (Right to buy) | $1.54 | 09/04/2020 | A(1) | 14 | (2) | 03/07/2024 | Common Stock | 14 | $0 | 14 | D | ||||
Stock Options (Right to buy) | $41.975 | 09/04/2020 | D(1) | 357 | (2) | 09/16/2026 | Common Stock | 357 | $0 | 0 | D | ||||
Stock Options (Right to buy) | $1.54 | 09/04/2020 | A(1) | 357 | (2) | 09/16/2026 | Common Stock | 357 | $0 | 357 | D | ||||
Stock Options (Right to buy) | $14.7 | 09/04/2020 | D(1) | 30,411 | (2) | 06/22/2027 | Common Stock | 30,411 | $0 | 0 | D | ||||
Stock Options (Right to buy) | $1.54 | 09/04/2020 | A(1) | 30,411 | (2) | 06/22/2027 | Common Stock | 30,411 | $0 | 30,411 | D | ||||
Stock Options (Right to buy) | $7.48 | 09/04/2020 | D(1) | 16,600 | (3) | 04/04/2029 | Common Stock | 16,600 | $0 | 0 | D | ||||
Stock Options (right to buy) | $1.54 | 09/04/2020 | A(1) | 16,600 | (3) | 04/04/2029 | Common Stock | 16,600 | $0 | 16,600 | D |
Explanation of Responses: |
1. All transactions reported on this form involve the repricing of stock options with an exercise price greater than $1.54 to an exercise price of $1.54, as approved by shareholders at the 2020 annual meeting, with certification of the shareholder vote as of September 4, 2020. |
2. Currently exercisable. |
3. 12,450 shares are currently vested; 2,075 shares vest on each of 10/4/2020 and 1/4/2021. |
4. Share ownership totals have been adjusted to reflect a 1 for 10 reverse stock split effected by the issuer on October 29, 2019. |
/s/ Bob Myers | 09/09/2020 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |